FDC India (FDC.NS)

Executive Summary

FDC Limited is a vertically integrated Indian pharmaceutical company with over 85 years of experience in branded generics, APIs, and nutraceuticals. The company operates across therapeutic segments such as gastroenterology, vitamins, anti-infectives, and dermatology, offering a broad portfolio of dosage forms. Its vertical integration provides cost advantages and quality control, while a strong domestic presence and growing exports to regulated markets underpin its business model. With a market capitalization of approximately ₹596 billion, FDC is well-positioned to capitalize on the growing demand for affordable healthcare in India and abroad. Looking ahead, FDC is expected to sustain its growth through new product launches and expansion in high-potential therapeutic areas. The company’s focus on dermatology and nutraceuticals, combined with its robust R&D pipeline, supports its competitive edge. Key catalysts include the launch of a new branded dermatology product, potential FDA approvals for generic drugs, and strategic partnerships to enhance its international footprint. These initiatives, along with its strong financial fundamentals, are likely to drive near-term growth and shareholder value.

Upcoming Catalysts (preview)

• Q3 2026Launch of new branded dermatology product in India70% success
• Q4 2026USFDA ANDA approval for a key generic drug50% success
• Q3 2026Strategic partnership for nutraceutical distribution in emerging markets60% success